Ana Vitória Costa¹

Ms. Ana Vitória Costa¹

Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
RRRafael Rodrigues Rodrigues
Rafael Rodrigues Rodrigues
JMJaqueline Freitas Motta
Jaqueline Freitas Motta
MFMarcos Roberto Alves Ferreira
Marcos Roberto Alves Ferreira
CJClóvis Moreira Júnior
Clóvis Moreira Júnior
MAMariliana Luiza Ferreira Alves
Mariliana Luiza Ferreira Alves
FCFabricio Rochedo Conceição
Fabricio Rochedo Conceição

4 July 2025 in Veterinary Vaccine
Verified
Journal Article
Open access
NCNeida Conrad
Neida Conrad
VZVitória Sequeira Gonçalves Zorzi
Vitória Sequeira Gonçalves Zorzi
IMIlana Mazzoleni
Ilana Mazzoleni
Ana Vitória Costa¹Ana Vitória Costa¹
Ana Vitória Costa¹
RPRenan Eugênio Araújo Piraine
Renan Eugênio Araújo Piraine
FLFabio Leite
Fabio Leite

1 January 2024 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
PDF file
NONatasha de Oliveira
Natasha de Oliveira
FSFrancisco Denis Souza Santos
Francisco Denis Souza Santos
ANAmilton Clair Pinto Seixas Neto
Amilton Clair Pinto Seixas Neto
LBLiana Nunes Barbosa
Liana Nunes Barbosa
MBMiguel Andrade Bilhalva
Miguel Andrade Bilhalva
FCFabricio Conceição
Fabricio Conceição
Since the inception of COVID-19 pandemic, there has been a challenging race for the development of precise diagnostic tests. Specific SARS-CoV-2 serological assays are the main tools used to estimate the rate of past infections or herd immunity in epidemiological studies, in addition to being helpful in guiding public health management policies. In this study, an in-house ELISA based on the construct of SARS-CoV-2 nucleocapsid (N) proteins, named rCoV2, rCoV4, and rCoV7, showed diagnostic performance for the detection of IgG antibodies. Sensitivity was evaluated in serum samples from patients with mild to moderate or severe COVID-19 infections, which were collected at different time points, while specificity was evaluated using pre-pandemic sera. In samples from mild to moderate cases obtained ≥16 days after the onset of symptoms, the sensitivities for rCoV2, rCoV4, and rCoV7 were 66.7%, 75%, and 77.8%, respectively. For samples from severe cases, the sensitivity was above 80% for all constructs. All proteins showed high specificity (94-98%). Overall, rCoV7 (C-terminus N-protein portion) showed better diagnostic performance, with 62.3% sensitivity in moderate and severe cases and 96.6% specificity. The SARS-CoV-2 ELISA using N-protein-based constructs could be a promisor tool for investigate the epidemiology of COVID-19 and monitor population-level serosurveillance.

1 January 2026 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
RFRenata Nobre da Fonseca
Renata Nobre da Fonseca
NCNeida Conrad
Neida Conrad
VZVitória Sequeira Gonçalves Zorzi
Vitória Sequeira Gonçalves Zorzi
Ana Vitória Costa¹Ana Vitória Costa¹
Ana Vitória Costa¹
PRPaulo Ricardo Centeno Rodrigues
Paulo Ricardo Centeno Rodrigues
FLFabio Leite
Fabio Leite
Bacillus toyonensis is a spore-forming bacterium widely used as a probiotic for animals and humans. It has been reported for its immunomodulatory properties, particularly in enhancing innate and acquired immune responses. One mechanism involved in immune modulation is the capacity of B. toyonensis to stimulate immune cells to produce cytokines. This study investigated the immunomodulatory effects of Bacillus toyonensis BCT-7112T on the macrophage-like cell line RAW 264.7. Cells were stimulated with B. toyonensis vegetative cells (live and killed), spores (viable and non-viable), DNA, and conditioned media for 24, 48, and 72 hours to evaluate proliferation. Additionally, cells were stimulated for 1, 8, and 24 hours and analyzed by qPCR for the transcription of Tnf-α, Il4, Il10, Nuclear Factor kappa Beta (Nfkβ), and Toll-like receptor 2 (Tlr-2). All B. toyonensis stimuli induced cell proliferation, with spores exhibiting the most significant increase (p < 0.05) across all time points. B. toyonensis also induced the transcription of Tnf-α, Il4, Il10 cytokines, Nfkβ, and Tlr-2, with the most pronounced effects (p<0.05) observed following stimulation with viable spores. Our findings suggest that B. toyonensis BCT-7112T has immunomodulatory effects through the activation of murine RAW 264.7 cells, supporting its potential as a model for studying probiotic immunomodulation.

Verified
Journal Article
Open access
PDF file
DDDias SInnott Dias
Dias SInnott Dias
Ana Vitória Costa¹Ana Vitória Costa¹
Ana Vitória Costa¹
MSMariana Silveira Mello Silva²
Mariana Silveira Mello Silva²
ASAnella Saggese
Anella Saggese
YLYlenia De Luca
Ylenia De Luca
Ezio RiccaEzio Ricca
Ezio Ricca
The search for next-generation probiotics derived from the human gut microbiota has intensified due to their potential beneficial effects in modulating immunity and preventing diseases. Spore-forming bacteria are attractive probiotic candidates due to their functional traits and unique resilience, which offer high stability to commercial formulations. In this study, spore-forming bacteria isolated from human fecal samples were screened. Two strains, Bacillus spizizenii A1 and Priestia megaterium F6, were identified as non-hemolytic and not resistant to a panel of antibiotics relevant for spore formers. Both strains were characterized by using in silico and in vitro approaches, demonstrating relevant probiotic potential. The comparative analysis indicated B. spizizenii A1 as the most promising probiotic candidate due to the resistance of its spores to simulated gastric conditions and for its antioxidant, antimicrobial, and antibiofilm activities. Strain A1 combines a safety profile with functional probiotic traits and is therefore a strong candidate for further in vivo evaluation and future development as a next-generation probiotic.